Neuroprotective Activity of a Nanoparticulate Formulation of the GlycineB Site Antagonist MRZ 2/576 in Transient Focal Ischaemia in Rats

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Arzneimittelforschung

• Publication date

  2002-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-0031-1299875PMID 11963643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protection against post-ischaemic neuronal loss in gerbil hippocampal CA1 by glycineb and AMPA antagonists

  2005cited by this paper
• Novel glycineB antagonists show neuroprotective activityin vivo

  2005cited by this paper
• Glycine antagonists for the treatment of stroke: a literature survey (1997-1999).

  2000cited by this paper
• Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system.

  2000cited by this paper
• Nanosuspensionen - Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 1. Mitteilung: Herstellung und Eigenschaften

  1999cited by this paper
• Subunit- and site-specific pharmacology of the NMDA receptor channel.

  1999cited by this paper
• The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies.

  1999cited by this paper
• Limiting Neurological Damage After Stroke

  1999cited by this paper
• Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles

  1999cited by this paper
• Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro.

  1998cited by this paper
• Glutamate in CNS disorders as a target for drug development: an update.

  1998cited by this paper
• Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

  1998cited by this paper
• Reevaluation of ACEA 1021 as an antagonist at the strychnine-insensitive glycine site of the N-methyl-D-aspartate receptor.

  1998cited by this paper
• The Effects of SB 206284A, a Novel Neuronal Calcium-Channel Antagonist, in Models of Cerebral Ischemia

  1997cited by this paper
• Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization.

  1997cited by this paper
• Neuroprotective Effect of NMDA Receptor Glycine Recognition Site Antagonism Persists When Brain Temperature is Controlled

  1997cited by this paper
• Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles

  1997cited by this paper
• Protection of Neurological Function in Stroke Models and Neuroprotective Properties of Lubeluzole (Part 1 of 2)

  1997cited by this paper
• Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes

  1997cited by this paper
• Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection.

  1996cited by this paper
• In vivo Models of Cerebral Ischemia: Effects of Parenterally Administered NMDA Receptor Glycine Site Antagonists

  1995cited by this paper
• Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).

  1995cited by this paper
• Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduces Neocortical Infarction

  1994influential reference
• Post-traumatic brain hypothermia reduces histopathological damage following concussive brain injury in the rat

  1994cited by this paper
• Treatment with an AMPA Antagonist 12 Hours following Severe Normothermic Forebrain Ischemia Prevents CA1 Neuronal Injury

  1993cited by this paper
• The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model.

  1992cited by this paper
• Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia.

  1991cited by this paper
• Reversible middle cerebral artery occlusion without craniectomy in rats.

  1989cited by this paper
• Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.

  1986cited by this paper

• Drug delivery strategies for neuroprotective therapy in ischemic stroke: Application of nanotechnology

  2025cites this paper
• Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies

  2020cites this paper
• Brain Drug Delivery Systems for the Stroke Intervention and Recovery.

  2017cites this paper
• Nanoparticle transport across the blood brain barrier

  2016cites this paper
• Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.

  2016cites this paper
• Potential use of nanomedicines for drug delivery across the BBB in health and diseased brain.

  2016cites this paper
• Nanomaterials in stroke treatment: perspectives.

  2013cites this paper
• Topical Review Nanomaterials in Stroke Treatment Perspectives

  2013cites this paper
• Therapeutic Hypothermia: Critical Review of the Molecular Mechanisms of Action

  2010cites this paper
• Influence of the antagonist of the glycine site of NMDA receptors, MRZ 2/576, on the anticonvulsant activity of conventional antiepileptic drugs in mice.

  2005cites this paper
• Neurotransmitter release in experimental stroke models: the role of glutamate-GABA interaction.

  2004cites this paper
• Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.

  2003cites this paper
• From Polymer Chemistry and Physicochemistry to Nanoparticulate Drug Carrier Design and Applications

  2003cites this paper
• Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications.

  2003cites this paper